TD Cowen raised the firm’s price target on Alnylam (ALNY) to $371 from $282 and keeps a Buy rating on the shares. The firm updated its ...

Alnylam's Yvonne Greenstreet, at #STATSummit, predicts vutrisiran will become multibillion-dollar product for ...

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for ...

Alnylam Pharmaceuticals ALNY has outperformed the market over the past 20 years by 13.16% on an annualized basis producing an ...

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

That course has changed slightly. On Tuesday, Maraganore launched a start-up, City Therapeutics, that builds on his 20-year ...

Scotiabank started coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note issued to ...

City Therapeutics, based in Cambridge, is developing new medicines that use RNA interference, or RNAi, to silence genes and ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report)’s stock price reached a new 52-week high on Tuesday after Bank of America raised their price target on the stock from $307.00 to $314.00.

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR ...